Literature DB >> 16429847

Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization.

S Unver1, E M Atasoyu, T R Evrenkaya, N Ozmen, Y Arslan, B Karaman.   

Abstract

Despite being widely reported in patients with neoplasms, vena cava superior (VCS) syndrome linked to thrombosis is a major catheter complication that can be encountered during the use of the hemodialysis catheter. Antithrombin III (AT-III), responsible for a large part of thrombin inactivation capacity in plasma, is the most powerful inhibitor of the thrombosis process. This report describes a case of VCS syndrome developing two weeks following the extraction of a right-sided subclavian catheter in a patient transferred from peritoneal dialysis to hemodialysis for one week due to leakage. The patient presented complaining of swelling and pain in the right arm. At Doppler examination, total thrombosis was observed in the subclavian and internal jugular vein. At advanced examinations due to lack of response to heparin and clinical worsening, VCS and AT-III deficiency were determined. Following thrombolytic therapy with streptokinase, AT-III levels were raised by the administration of plasma, and clinical and radiological stabilization was established by continuing heparin and continuous oral anticoagulant therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16429847     DOI: 10.5414/cnp65071

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.

Authors:  Raffaella Salmi; Piergiorgio Gaudenzi; Filippo Di Todaro; Pierluigi Morandi; Ingrid Nielsen; Roberto Manfredini
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Vena Cava Superior Syndrome Six Years after Central Venous Catheter Removal in a Patient on Hemodialysis.

Authors:  Michelle Janssen; Susan Logtenberg
Journal:  Case Rep Nephrol Dial       Date:  2022-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.